New Zealand’s Pharmaceutical Management agency PHARMAC today announced the approval of an agreement with the local subsidiary of Swiss biotech firm Actelion (SIX: ATLN) to list Veletri (epoprostenol) injection in Part II of Section H (the Hospital Medicines List or HML) of the Pharmaceutical Schedule.
Epoprostenol will be listed under the Prostacyclin Analogues heading in the Vasodilators therapeutic subgroup of the Cardiovascular System therapeutic group in Part II of Section H of the Pharmaceutical Schedule from 1 September 2015 at the following price (ex-manufacturer, excluding GST).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze